Mimir
Mimir
The global cardiac rhythm management (CRM) devices market was valued at approximately USD 20.8–27.1 billion in 2024–2025 depending on the research source, with the most frequently cited estimates clustering around USD 20.8–21.1 billion (Grand View Research; Maximize Market Research). North America is the dominant regional market, accounting for roughly 45% of global revenue in 2024, with the U.S. holding the largest share within that region. Pulse generators constitute the overwhelming majority of product-type revenue at nearly 80%, and hospitals represent the primary end-user channel at over 53% of global sales.
Basis — 2024 anchor of USD 20.77B and 2033 endpoint of USD 36.19B are directly stated by Grand View Research (2025). Intervening years 2025–2032 are estimated by applying the disclosed 6.35% CAGR compounded annually from the 2024 base: Year N = 20.77 × (1.0635)^(N−2024). 2026 estimate: 20.77 × (1.0635)^2 = ~23.52B. 2028 estimate: 20.77 × (1.0635)^4 = ~26.65B. 2030 estimate: 20.77 × (1.0635)^6 = ~30.17B. The 360iResearch 2026 point of USD 29.52B is noted as an alternative but is not used here to avoid mixing methodologies; the Grand View Research series is used for internal consistency. The 2025 point from Maximize Market Research (USD 21.12B) is broadly consistent with the GVR CAGR-derived 2025 figure of ~22.09B, lending partial corroboration.
The most analytically notable feature of this market is the extreme divergence in size estimates across research firms — ranging from USD 14.8 billion (Future Market Insights) to USD 27.1 billion (360iResearch) for the same base year of 2025, a nearly 2× spread. This is most plausibly explained by differing category scope: narrower definitions may exclude remote monitoring systems, cardiac resynchronization therapy (CRT) devices, or implantable loop recorders, while broader definitions bundle in adjacent electrophysiology or monitoring hardware. The CAGR spread is equally wide — from 2.9% (Future Market Insights) to 10.44% (360iResearch) — suggesting that the lower-CAGR sources are projecting from a larger base while the higher-CAGR sources are projecting from a smaller one, a mathematical artifact of differing base-year valuations. The pulse generators segment's 79.46% share of product revenue underscores that the market is structurally concentrated in a single product sub-type, meaning overall market growth is heavily dependent on pacemaker and ICD implant volumes rather than on diversification across device classes. The hospital channel's 53.49% share — while dominant — also implies that nearly half of revenue flows through non-hospital settings, a structural detail that may reflect the growing role of ambulatory surgical centers in device implantation, though sub-channel granularity is not available in the retrieved data.
Limitations: Market size estimates for 2024–2025 vary substantially across sources (USD 14.8B to USD 27.1B), most likely reflecting differing category definitions and base-year methodologies rather than measurement error alone. The Data Bridge Market Research figure (USD 24.10B for 2024) carries a publication date of February 2022, making it potentially stale relative to post-pandemic device volume recovery; readers should weight more recent sources accordingly. No unit-volume or installed-base data were available in the retrieved data; all sizing is value-based. Sub-segment data (e.g., pacemakers vs. ICDs vs. CRT devices; ambulatory surgery centers vs. home care) are not broken out in the retrieved data. North America regional figures are derived estimates scaled from disclosed global totals and regional share percentages, not independently reported regional absolutes. The market size trend intermediate points for 2025, 2026, 2028, and 2030 are CAGR-derived estimates, not directly reported figures.